Epilepsy Research
Volume 24, Issue 3 , Pages 163-172 , July 1996

Dose-dependent metabolism of carbamazepine in humans

Received 4 December 1995 ,Revised 8 February 1996 ,Accepted 13 February 1996.

References 

  1. Battino D, Bossi L, Croci D, Franceschetti S, Gomeni C, Moise A, et al. Carbamazepine plasma levels in children and adults: influence of age, dose, and associated therapy. Ther. Drug Monit. 1980;2:315–322
  2. Bernus I, Dickinson RG, Hooper WD, Eadie MJ. Early stage autoinduction of carbamazepine metabolism in humans. Eur. J. Clin. Pharmacol. 1994;47:355–360
  3. Bernus I, Hooper WD, Dickinson RG, Eadie MJ. Metabolism of carbamazepine and co-administered anticonvulsants during pregnancy. Epilepsy Res. 1995;21:65–75
  4. Bertilsson L, Tomson T, Tybring G. Pharmacokinetics: time-dependent changes — autoinduction of carbamazepine epoxidation. J. Clin. Pharmacol. 1986;26:459–462
  5. Cloyd JC, Levy RH, Wedlund PH. Relationship between carbamazepine concentration and extent of enzyme autoinduction. Epilepsia. 1986;27:592
  6. Cotter LM, Eadie MJ, Hooper WD, Lander CM, Smith MT, Tyler JH. The pharmacokinetics of carbamazepine. Eur. J. Clin. Pharmacol. 1977;12:451–456
  7. Cotter LM, Smith GA, Hooper WD, Tyrer JH, Eadie MJ. The bioavailability of carbamazepine. In: 4th Ed.. Proc. Aust. Assoc. Neurol. 12:1975;p. 123–128
  8. Eadie MJ, Hooper WD. Intermittent carbamazepine intoxication possibly related to altered absorption characteristics of the drug. Med. J. Australia. 1987;146:313–316
  9. Eichelbaum M, Ekbom K, Bertilsson L, Ringberger VA, Rane A. Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. Eur. J. Clin. Pharmacol. 1975;8:337–341
  10. Faigle JW, Feldmann KF. Carbamazepine. Chemistry and biotransformation. In:  Levy RH, et al. editor. Antiepileptic Drugs. 4th Ed.. New York, NY: Raven; 1995;p. 499–513
  11. Gardner MJ, Altman DG. Statistics with Confidence. London, UK: British Medical Journal; 1988;
  12. Gerardin AP, Abadie FV, Campestrini JA. Pharmacokinetics of carbamazepine in normal humans after single and repeated oral doses. J. Pharmacokin. Biopharm. 1976;4:521–535
  13. Hartley R, Lucock MD, Ng PC, Forsythe WI, McLain B, Bowmer CJ. Factors influencing plasma level/dose ratios of carbamazepine and its major metabolites in epileptic children. Ther. Drug Monit. 1990;12:438–444
  14. Hooper WD, DuBetz DK, Eadie MJ, Tyrer JH. Preliminary observations on the clinical pharmacology of carbamazepine (Tegretol). In: Proc. Aust. Assoc. Neurol. 11:1974;p. 189–198
  15. Johanessen SI, Baruzzi A, Gomeni R, Strandjord RE, Morselli PL. Further observations on carbamazepine and carbamazepine-10,11-epoxide kinetics in epileptic patients. In:  Gardner-Thorp C, et al. editor. Antiepileptic Drug Monitoring. Tunbridge Wells, UK: Pitman; 1977;p. 110–127
  16. Kudriakova KB, Sirota LA, Rozova GI, Gorkov VA. Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites. Br. J. Clin. Pharmac. 1992;33:611–616
  17. Levy RH, Pitlick WH, Troupin AS, Green JR. Pharmacokinetic implications of chronic drug treatment in epilepsy: carbamazepine. In:  Benet LZ editors. The Effect of Disease States on Drug Pharmacokinetics. Washington, DC: American Pharmaceutical Association Academy of Pharmaceutical Sciences; 1976;p. 87–95
  18. Levy RH, Pitlick WH, Troupin AS, Green JR, Neal JM. Pharmacokinetics of carbamazepine in normal man. Clin. Pharmacol. Ther. 1975;17:657–668
  19. McKauge L, Tyrer JH, Eadie MJ. Factors influencing simultaneous concentrations of carbamazepine and its epoxide in plasma. Ther. Drug Monit. 1981;3:63–70
  20. Perucca E, Bittencourt P, Richens A. Effect of dose increments on serum carbamazepine concentration in epileptic patients. Clin. Pharmacokinet. 1980;5:576–582
  21. Rambeck B, May T, Juergens U. Serum concentrations of carbamazepine and its epoxide and diol metabolites in epileptic patients: the influence of dose and comedication. Ther. Drug Monit. 1987;9:298–303
  22. Tomson T, Svensson JO, Hilton-Brown P. Relationship of intraindividual dose to plasma concentration of carbamazepine: indication of dose-dependent induction of metabolism. Ther. Drug Monit. 1989;11:533–539

PII: 0920-1211(96)00011-3

Epilepsy Research
Volume 24, Issue 3 , Pages 163-172 , July 1996

Article Tools